BPC July 02 update

Alector ALEC shares surge on deal with ​Glaxo GSK +57%; Arrowhead ARWR pauses cystic fibrosis trial -26%

Price and Volume Movers

GlaxoSmithKline plc (NYSE: GSK) and Alector Inc (NASDAQ: ALEC) announced a collaboration for the development of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101), for various neurodegenerative diseases including Parkinson's disease and Alzheimer's disease. Alector recives $700 million upfront and up to $1.5 billion in milestone payments. Shares of Alector closed up 57% to $35.21.

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares fell 26% to $63.13 on news it has paused its Phase 1/2 trial of ARO-ENaC, as a treatment for patients with cystic fibrosis (CF), after receiving a preliminary update from an ongoing chronic toxicology trial in rats that contained unexpected signals of local lung inflammation.

Iterum Therapeutics plc (NASDAQ:ITRM) shares closed down 38% to $1.42 following its announcement late-Thursday that the FDA has identified deficiencies that preclude the discussion of labeling and post marketing requirements/commitments for its (New Drug Application) NDA for sulopenem. The assigned PDUFA date is July 25, 2021. Shares closed Friday down 38% to $1.42.


Other major price movers (stocks priced > $1.00, volume > 50k listed on NASDAQ/NYSE):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:


Adial Pharmaceuticals, Inc. (ADIL): $2.94; +16%.

Elevation Oncology, Inc. (ELEV): $15.33; +16%.

BioLineRx Ltd. (BLRX): $3.35; +16%.

IVERIC bio, Inc. (ISEE): $7.94; +12%.

Clearside Biomedical, Inc. (CLSD): $5.38; +11%.


Alterity Therapeutics Limited (ATHE): $1.75; -18%.

Citius Pharmaceuticals, Inc. (CTXR): $2.15; -17%.

Kintara Therapeutics, Inc. (KTRA): $1.93; -16%.

Atossa Therapeutics, Inc. (ATOS): $5.37; -16%.

Cerevel Therapeutics Holdings, Inc. (CERE): $23.13; -14%.

Pipeline updates below:

Pipeline Database Updates

Drug Price Stage Catalyst Market Cap

ARWR – Arrowhead Pharmaceuticals Inc.
Cystic Fibrosis

+1.27  +2%
Phase 1/2 Phase 1/2 trial paused following a trial in rats that contained unexpected signals of local lung inflammation - July 2, 2021.
$6.8 billion

OCGN – Ocugen, Inc.
COVID-19 vaccine

+0.39  +5%
Phase 3 Phase 3 data from partner Bharat Biotech noted efficacy rate of 78%; 93% against severe disease; 65% against Delta variant. BLA filing to be submitted instead of FDA Emergency Use Authorization Application - June 10, 2021.
$1.6 billion